Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Shi, Yuankai; Jia, Bo; Xu, Wei; Li, Wenyu; Liu, Ting; Liu, Peng; Zhao, Weili; Zhang, Huilai; Sun, Xiuhua; Yang, Haiyan; Zhang, Xi; Jin, Jie; Jin, Zhengming; Li, Zhiming; Qiu, Lugui; Dong, Mei; Huang, Xiaobing; Luo, Yi; Wang, Xiaodong; Wang, Xin; Wu, Jianqiu; Xu, Jingyan; Yi, Pingyong; Zhou, Jianfeng; He, Hongming; Liu, Lin; Shen, Jianzhen; Tang, Xiaoqiong; Wang, Jinghua; Yang, Jianmin; Zeng, Qingshu; Zhang, Zhihui; Cai, Zhen; Chen, Xiequn; Ding, Kaiyang; Hou, Ming; Huang, Huiqiang; Li, Xiaoling; Liang, Rong; Liu, Qifa; Song, Yuqin; Su, Hang; Gao, Yuhuan; Liu, Lihong; Luo, Jian‐Min; Su, Liping; Sun, Zimin; Tan, Huo; Wang, Huaqing; Wang, Jingwen; Wang, Shuye; Zhang, Hongyu; Zhang, Xiaohong; Zhou, Daobin; Bai, Ou; Wu, Gang; Zhang, Liling; Zhang, Yizhuo

doi:10.1186/s13045-017-0439-6

Public

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Published in Journal of Hematology & Oncology • Mar 15, 2017

Authors:

Yuankai Shi

Bo Jia

Wei Xu

Abstract

The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cel...

Subject

Medicine

Internal medicine

Neutropenia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!